Literature DB >> 29017430

Characterizing neurocognitive late effects in childhood leukemia survivors using a combination of neuropsychological and cognitive neuroscience measures.

Ellen Van Der Plas1,2, Lauren Erdman3,4, Brian J Nieman1,5,6,7, Rosanna Weksberg3,8,9, Darci T Butcher3, Deborah L O'connor1,10, Susanne Aufreiter1, Johann Hitzler8,11, Sharon L Guger12, Russell J Schachar2,9,13, Shinya Ito1,14,15, Brenda J Spiegler8,12.   

Abstract

Knowledge about cognitive late effects in survivors of childhood acute lymphoblastic leukemia (ALL) is largely based on standardized neuropsychological measures and parent reports. To examine whether cognitive neuroscience paradigms provided additional insights into neurocognitive and behavioral late effects in ALL survivors, we assessed cognition and behavior using a selection of cognitive neuroscience tasks and standardized measures probing domains previously demonstrated to be affected by chemotherapy. 130 ALL survivors and 158 control subjects, between 8 and 18 years old at time of testing, completed the n-back (working memory) and stop-signal (response inhibition) tasks. ALL survivors also completed standardized measures of intelligence (Wechsler Intelligence Scales [WISC-IV]), motor skills (Grooved Pegboard), math abilities (WIAT-III), and executive functions (Delis-Kaplan Executive Function System). Parents completed behavioral measures of executive functions (Behavior Rating Inventory of Executive Function [BRIEF]) and attention (Conners-3). ALL survivors exhibited deficiencies in working memory and response inhibition compared with controls. ALL survivors also exhibited deficits on WISC-IV working memory and processing speed, Grooved Pegboard, WIAT-III addition and subtraction fluency, and numerical operations, as well as DKEFS number-letter switching. Parent reports suggested more attention deficits (Conners-3) and behavioral difficulties (BRIEF) in ALL survivors compared with referenced norms. Low correspondence between standardized and experimental measures of working memory and response inhibition was noted. The use of cognitive neuroscience paradigms complements our understanding of the cognitive deficits evident after treatment of ALL. These measures could further delineate cognitive processes involved in neurocognitive late effects, providing opportunities to explore their underlying mechanisms.

Entities:  

Keywords:  Childhood cancer survivor; cognitive neuroscience; neuropsychology; responseinhibition; working memory

Mesh:

Year:  2017        PMID: 29017430     DOI: 10.1080/09297049.2017.1386170

Source DB:  PubMed          Journal:  Child Neuropsychol        ISSN: 0929-7049            Impact factor:   2.500


  9 in total

1.  Translationally relevant mouse model of early life cancer and chemotherapy exposure results in brain and small intestine cytokine responses: A potential link to cognitive deficits.

Authors:  Jan Pieter Konsman; Collin J Laaker; Kelsey R Lloyd; Adam Hiltz; Brittany L Smith; Marissa A Smail; Teresa M Reyes
Journal:  Brain Behav Immun       Date:  2021-10-14       Impact factor: 7.217

2.  Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia.

Authors:  Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman
Journal:  Pediatr Res       Date:  2020-11-17       Impact factor: 3.953

3.  Sex-Based Differences in Functional Brain Activity During Working Memory in Survivors of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Kellen Gandy; Matthew A Scoggins; Nicholas Phillips; Ellen van der Plas; Slim Fellah; Lisa M Jacola; Ching-Hon Pui; Melissa M Hudson; Wilburn E Reddick; Ranganatha Sitaram; Kevin R Krull
Journal:  JNCI Cancer Spectr       Date:  2022-03-02

4.  Cognitive function of children and adolescent survivors of acute lymphoblastic leukemia: A meta-analysis.

Authors:  Kalliopi Mavrea; Vasiliki Efthymiou; Katerina Katsibardi; Konstantinos Tsarouhas; Christina Kanaka-Gantenbein; Demetrios A Spandidos; George Chrousos; Antonis Kattamis; Flora Bacopoulou
Journal:  Oncol Lett       Date:  2021-02-05       Impact factor: 2.967

5.  Linguistic-Cognitive Outcomes in Children with Acute Lymphoid Leukemia: An Exploratory Study.

Authors:  Michelle Miranda Pereira; Debora Maria Befi-Lopes; Aparecido José Couto Soares; Fernanda Chiarion Sassi; Claudia Regina Furquim de Andrade
Journal:  J Multidiscip Healthc       Date:  2021-06-01

6.  Characterizing academic performance in pediatric acute lymphoblastic leukemia with population-based achievement tests.

Authors:  Hend M Al-Kaylani; Erin E Reasoner; Bradley T Loeffler; Sarah L Mott; Susan Madasu; Audrey Liu; Kathleen Langbehn; Amy L Conrad; David Dickens; Amanda Grafft; Lyndsay Harshman; Arunkumar J Modi; Ellen van der Plas
Journal:  Cancer Rep (Hoboken)       Date:  2021-09-30

7.  Effects of chemotherapy for acute lymphoblastic leukemia on cognitive function in animal models of contemporary protocols: A systematic literature review.

Authors:  Tyler C Alexander; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2021-08-03       Impact factor: 9.052

8.  Quantitative MRI outcomes in child and adolescent leukemia survivors: Evidence for global alterations in gray and white matter.

Authors:  Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Brenda J Spiegler; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman
Journal:  Neuroimage Clin       Date:  2020-09-15       Impact factor: 4.881

9.  Impact of non-CNS childhood cancer on resting-state connectivity and its association with cognition.

Authors:  Janine S Spitzhüttl; Martin Kronbichler; Lisa Kronbichler; Valentin Benzing; Valerie Siegwart; Manuela Pastore-Wapp; Claus Kiefer; Nedelina Slavova; Michael Grotzer; Claudia M Roebers; Maja Steinlin; Kurt Leibundgut; Regula Everts
Journal:  Brain Behav       Date:  2020-11-18       Impact factor: 2.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.